BioSpace News Archive

CARGO Therapeutics, Inc. (CARGO) today announced the addition of independent directors to the Board of Directors following its recent $200 million Series A financing in March 2023.

Tarsus Pharmaceuticals, Inc., whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that XDEMVY™ 0.25% is now available at pharmacies nationwide for prescription.

Kansas City University Associate professor Ehab Sarsour, MSc, PhD, and student-researchers have discovered a new and promising avenue for treating pancreatic cancer by treating the tumor microenvironment by repurposing a drug designed for hyperlipidemia.

Paragonix Technologies, a leading organ transplant company, received US Food and Drug Administration (“FDA”) clearance for its next-generation donor lung preservation system, BAROguard™.

LivaNova PLC, a market-leading medical technology company, announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at the Baird Global Healthcare Conference in New York.

BostonGene, NEC Corporation and Japan Industrial Partners announced the formation of BostonGene Japan Inc., a Tokyo-based joint venture aimed at advancing personalized medicine and dramatically improving patient outcomes.

Elucida Oncology announced that Ramzi Benamar, a seasoned financial leader with a proven track record in the life sciences industry, has been appointed as Chief Financial Officer, effective September 1, 2023.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”) announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2023, taking place in Amsterdam, Netherlands on August 25 - 28, 2023.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX203 versus optimized immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson’s disease (PD).

YS Biopharma Co., Ltd. announced that the Company’s Founder and Chairperson, Mr. Yi Zhang, and its Director and Chief Executive Officer, Dr. Hui Shao, have purchased 429,188 of the Company’s ordinary shares at an average price of $1.407 per share, and 46,300 of the Company’s ordinary shares at an average price of $1.46 per share, respectively, on the open market.